About this trial
A study to help understand what forms of folic acid are most effective to increase folate status during pregnancy for the best protection against neural tube defects
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Currently trying to become pregnant;
Aged 19-42 years;
Low risk for an NTD-affected pregnancy
Disqualifiers
Trying to conceive for ≥6 months (as ~90% of pregnancies occur after 6 months of trying);
Diagnosed ovulatory disorders (polycystic ovary syndrome, endometriosis, or menstrual irregularity);
More than 2 miscarriages in the past year;
Undergoing fertility assistance (including current IVF or intrauterine insemination);
Trial design
Parallel
Treatments tested in this trial
Folic Acid
Dietary supplementfolic acid (0.6 mg)
5-MTHF (5-methyltetrahydrofolate)
Dietary supplement0.625 mg/d (6S)-5-MTHF
Treatment groups
Trial outcomes
Primary outcomes
RBC folate
•Maternal RBC folate concentrations (nmol/L)
Secondary outcomes
Maternal plasma placental growth factor (pg/mL)
A novel biomarker with increasing use in clinical practice due to a discriminatory capacity for fetal growth restriction vs a small, but healthy fetus
Other outcomes
Human milk total folate concentrations
Unmetabolized folic acid, reduced folate forms (nmol/L), and folate binding protein
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University of British Columbia
Lead sponsor
University of Saskatchewan
Collaborator
This trial is not recruiting at the moment. You can still explore other options: